Financial PerformanceThe company reported no revenues and a net loss of $4.11 per share, which is significantly higher than consensus estimated net loss of $1.29 per share.
Investor SentimentInvestors are expected to be more focused on later-stage ALXN-1840 and anticipate incremental updates from MNPR-101-Lu to have a muted impact on share price in the near term.
Regulatory ChallengesProviding proof of fecal excretion of copper might require an additional study, posing a potential regulatory hurdle for ALXN1840's approval.